Saved in:
| Main Author: | |
|---|---|
| Format: | Recurso digital |
| Language: | |
| Published: |
Zenodo
2022
|
| Subjects: | |
| Online Access: | https://doi.org/10.5281/zenodo.7086505 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866901681004871680 |
|---|---|
| author | Dr. Sumood Abdulla Ahmed |
| author_facet | Dr. Sumood Abdulla Ahmed |
| contents | <p><strong>Background: </strong>Ectopic pregnancies are a life-threatening emergency since they can invade maternal blood vessels, causing catastrophic hemorrhage and it is the leading cause of maternal mortality in the first trimester, and it accounts for 3 % of all pregnancy-related deaths even in developed countries.<strong> Objectives: </strong>To investigate the predictive factors for the requirement of additional doses of methotrexate in women with ectopic pregnancy treated with a single dose methotrexate regimen.<strong> Study design & settings:</strong> A prospective study was conducted on the gynecological and obstetrics department in Salah Aldin teaching hospital for the one-year duration from the 1<sup>st</sup> of Feb. 2020 to the end of Nov. 2020. Whereas 125 patients were included in this study divided into two groups [one group A (75) was treated with a single dose of methotrexate and group B (50) with multiple doses].<strong> Results</strong>: The mean age group was between 20-29 years; the patient with a success treatment rate with a single dose was 73.3%, while for those who were treated with multiple doses with 64% success rate. Highly significant reduction in serum ß-hCG for ectopic pregnant women treated with a single methotrexate dose after four days and seven days of treatment. The resolution time was 31±SD days for those who were treated with a single dose, while it was 56±SD days for the multiple doses. <strong>Conclusion:</strong> The single dose of the methotrexate therapy could be positively offered to most stable patients experiencing medical management of an ectopic pregnancy, and a decline in the serum level of β-hCG between days 1 and 4 is related with a high treatment success rate. The change in the serum level of β-hCG between days 1 and 4 appears to be an early predictive factor of an additional dose of methotrexate.</p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_7086505 |
| institution | Zenodo |
| language | |
| publishDate | 2022 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Early Prediction for the Requirement of Second or Third Dose Methotrexate in Women with Ectopic Pregnancy Treated with Single Dose Regimen Dr. Sumood Abdulla Ahmed Early prediction, Third dose methotrexate, Ectopic pregnancy <p><strong>Background: </strong>Ectopic pregnancies are a life-threatening emergency since they can invade maternal blood vessels, causing catastrophic hemorrhage and it is the leading cause of maternal mortality in the first trimester, and it accounts for 3 % of all pregnancy-related deaths even in developed countries.<strong> Objectives: </strong>To investigate the predictive factors for the requirement of additional doses of methotrexate in women with ectopic pregnancy treated with a single dose methotrexate regimen.<strong> Study design & settings:</strong> A prospective study was conducted on the gynecological and obstetrics department in Salah Aldin teaching hospital for the one-year duration from the 1<sup>st</sup> of Feb. 2020 to the end of Nov. 2020. Whereas 125 patients were included in this study divided into two groups [one group A (75) was treated with a single dose of methotrexate and group B (50) with multiple doses].<strong> Results</strong>: The mean age group was between 20-29 years; the patient with a success treatment rate with a single dose was 73.3%, while for those who were treated with multiple doses with 64% success rate. Highly significant reduction in serum ß-hCG for ectopic pregnant women treated with a single methotrexate dose after four days and seven days of treatment. The resolution time was 31±SD days for those who were treated with a single dose, while it was 56±SD days for the multiple doses. <strong>Conclusion:</strong> The single dose of the methotrexate therapy could be positively offered to most stable patients experiencing medical management of an ectopic pregnancy, and a decline in the serum level of β-hCG between days 1 and 4 is related with a high treatment success rate. The change in the serum level of β-hCG between days 1 and 4 appears to be an early predictive factor of an additional dose of methotrexate.</p> |
| title | Early Prediction for the Requirement of Second or Third Dose Methotrexate in Women with Ectopic Pregnancy Treated with Single Dose Regimen |
| topic | Early prediction, Third dose methotrexate, Ectopic pregnancy |
| url | https://doi.org/10.5281/zenodo.7086505 |